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One of the main regulators of gene expression during embryogenesis and stem cell differentiation is DNA
methylation. The recent identification of hydroxymethylcytosine (5hmC) as a novel epigenetic mark sparked
an intense effort to characterize its specialized enzymatic machinery and to understand the biological signif-
icance of 5hmC. The recent discovery of recurrent deletions and somatic mutations in the TET gene family,
which includes proteins that can hydroxylate methylcytosine (5mC), in a large fraction of myeloid malignan-
cies further suggested a key role for dynamic DNA methylation changes in the regulation of stem cell differ-
entiation and transformation.One of the major epigenetic modifications of the human genome
is methylation at the 5-position of cytosine (5mC). Genome-wide
reprogramming events during early embryonic development are
characterized by the loss and reacquisition of DNA methylation
(Hajkova et al., 2008, 2010; Surani et al., 2007), a process
orchestrated by DNAmethyltranferases (DNMTs) that are essen-
tial for the establishment andmaintenance of 5mC in the genome
(Li et al., 1992; Okano et al., 1999). The discovery that hydroxy-
methylcytosine (5hmC) is also abundant in embryonic stem cells
(ESCs) and adult cells (Ito et al., 2010; Koh et al., 2011; Kriaucio-
nis and Heintz, 2009; Song et al., 2011; Szwagierczak et al.,
2010; Tahiliani et al., 2009) prompted several studies aimed at
identifying enzymes that could generate 5hmC from 5mC in
mammalian cells and the role of this epigenetic modification in
the regulation of DNA methylation.
In tumor cells, the normal pattern of DNA methylation is often
altered, resulting in global hypomethylation of the genome in
conjunction with hypermethylation at CpG islands within the
promoters of critical genes such as tumor suppressors (Esteller,
2008). Recent studies have identified a novel class of epigenetic
mutations in myeloid malignancies. Specifically, deletions and
inactivating mutations in the TET2 gene were identified in almost
30% of all myeloid malignancies (Abdel-Wahab et al., 2009; Del-
hommeau et al., 2009; Jankowska et al., 2009; Langemeijer
et al., 2009). With the parallel discovery that the TET family of
proteins, TET1, TET2, and TET3, were able to modify DNA by
hydroxylating 5mC to 5hmC (Tahiliani et al., 2009), and in so
doing promote active DNA demethylation (Cortellino et al.,
2011; Guo et al., 2011; He et al., 2011), a new field in epigenetic
regulation has emerged aimed at understanding the role of
5hmC and TETs in development and disease pathogenesis.
5hmC and the TET Family Proteins
The role of 5mC in epigenetic regulation has been extensively
studied; however, until recently very little was known about therole of 5hmC, despite its identification in themammalian genome
several decades ago (Penn et al., 1972). In 2009, Kriaucionis and
Heintz showed that global 5hmC levels in the genome of mouse
Purkinje cells and granule neurons constitute approximately
0.6% and 0.2% of all nucleotides, respectively (Kriaucionis and
Heintz, 2009). In addition, Tahiliani et al. found that 5hmC levels
comprised 0.03% of total nucleotides in mouse ESCs (Tahiliani
et al., 2009). While these frequencies seem small, the biological
significance of 5hmC levels becomes apparent when compared
to 5mC, which is also considered to be a minor base in mamma-
lian DNA, constituting approximately 1% of all DNA bases in the
genome; yet, it plays a crucial role in the regulation of gene
expression. In the search for mammalian enzymes able tomodify
5mC, using computational analysis, Tahiliani et al. made the
discovery that human TET1, TET2, and TET3 all contain in their
C terminus a 2-oxoglutarate- (2-OG) and Fe(II)-dependant dioxy-
genase domain homologous to the thymidine hydroxylase
domain of the trypanosomal proteins JBP1 and JBP2 (Tahiliani
et al., 2009). Using WT and catalytic mutants of human and
mouse TET1, TET2, and TET3, it was subsequently shown that
all the TET proteins are able to convert 5mC to 5hmC in an
Fe(II) and a-ketoglutarate- (a-KG)-dependent manner in vitro
(Ito et al., 2010; Tahiliani et al., 2009). Although all three TET
proteins can catalyze 5hmC production from 5mC, only the over-
expression of TET1 and TET2 in vivo caused a global decrease in
5mC (Ito et al., 2010; Tahiliani et al., 2009). More recently it has
also been shown that the TET proteins are able to further oxidize
5hmC into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)
(Ito et al., 2011; He et al., 2011), raising the possibility that loss of
5mC may occur through TET-catalyzed oxidation followed by
decarboxylation. These findings and the subsequent identifica-
tion of 5hmC in many other mammalian tissues and cell types
(Globisch et al., 2010; Song et al., 2011) have prompted several
studies designed to investigate the role of this DNA modification
in epigenetic and transcriptional regulation.Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc. 193
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Figure 1. The Role of TET Proteins in Passive or
Active DNA Demethylation
(A) The inability of the maintenance methyltransferase,
DNMT1, to recognize 5hmC-containing DNA may lead to
passive demethylation following replication.
(B) Active DNA methylation can be catalyzed by TET-
mediated (i) hydroxylation of 5mC to 5hmC, followed by
AID and APOBEC-mediated (ii) deamination of 5hmC to
5hmU, or (iii) further carboxylation of 5hmC to 5caC by the
TET proteins and the subsequent cleavage of 5hmU or
5caC by DNA glycosylases (e.g., SMUG1, UNG, and TDG)
and replacement with cytosine by (iv) a base excision
repair (BER) enzymatic pathway.
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Deamination, and DNA Repair
The presence of 5hmC may contribute to both passive and
active DNAdemethylation in the genome (Figure 1). Maintenance
methylation normally follows replication, and this process may
be inhibited due to the inability by DNMT1 to recognize 5hmC
(Valinluck and Sowers, 2007), causing 5mC to be lost passively
during cell division by replacement with unmethylated cytosine.
However, during mammalian development the rapid loss of DNA
methylation immediately after fertilization (Hajkova et al., 2010;
Mayer et al., 2000; Oswald et al., 2000) and again in primordial
germ cells (Hajkova et al., 2002; Lee et al., 2002) within the period
of a single cell cycle suggests the presence of enzymes that can
actively remove 5mC independently of replication. In addition,
modifying methylation patterns in nonreplicating cells such as
neurons would require either direct enzymatic removal of the
methyl group from cytosine, a role once proposed for the meth-
ylated CpG DNA-binding protein MBD2b (Bhattacharya et al.,
1999), or excision and replacement of cytosine by DNA repair
pathways. Plants employ base excision repair (BER) to achieve
active demethylation by excising 5mC directly (Gehring et al.,
2009; Zhu, 2009); however, DNA glycosylases that recognize
5mC have not been identified in mammals.
Recent studies have shown that TET hydroxylases may cata-
lyze active DNA demethylation induced by oxidation of 5mC to
5hmC and its replacement with unmethylated cytosine by
a sequential deamination and BER pathway. DNA deaminases
of the activation-induced cytidine deaminase (AID)/APOBEC
family catalyze the conversion of cytosine to uracil and 5hmC
to 5hmU. AID is required for antibody diversification mediated
by somatic hypermutation and class switching in germinal center
B cells (Muramatsu et al., 1999, 2000). APOBEC1 is themost well
characterized of the APOBEC family of enzymes that catalyzes
the conversion of a C residue to U in apolipoprotein B mRNA, re-
sulting in a premature stop codon (Teng et al., 1993). Interest-
ingly, while AID expression was thought to be restricted to
lymphoid tissue, it was recently identified as a factor required
for DNA demethylation during reprogramming of somatic cells194 Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc.(Bhutani et al., 2010), and AID null mice have
been shown to exhibit significant defects in
genome-wide DNA demethylation in primordial
germ cells (Popp et al., 2010).
Two recent studies have now shown that
both AID and APOBEC can mediate active
DNA demethylation in mammalian cells in col-
laboration with TET hydroxylase activity andthe demethylation intermediate 5hmC. In the first study by
Guo et al., AID overexpression in HEK293 cells led to a signifi-
cant decrease of endogenous 5hmC levels induced by TET1
(Guo et al., 2011), and coexpression of these two enzymes
promoted the loss of 5mC. Given the abundance of 5hmC in
various regions of the brain such as the hippocampal dentate
gyrus (Mu¨nzel et al., 2010), the authors used adeno-associated
viruses to introduce TET1 or AID into this area of the adult
mouse brain to measure effects on 5hmC production and
stability. Overexpression of TET1 further increased 5hmC levels,
whereas overexpression of AID significantly decreased those of
5hmC, an observation supporting its role for 5hmC removal
in vivo (Guo et al., 2011). Active demethylation was also
analyzed at endogenous loci known to exhibit neuronal
activity-induced active DNA demethylation in adult dentate
granule cells (Ma et al., 2009). TET1 or AID overexpression
mediated significant decreases in CpG methylation levels at
these genomic loci and both TET1 and AID-induced demethyla-
tion was accompanied by a significant upregulation in the
expression of these genes in vivo (Guo et al., 2011). Repeating
this experiment using shRNAs to target both endogenous
TET1 and TET2 and the most abundant endogenously ex-
pressed deaminase in this tissue, APOBEC1, showed that
demethylation was impaired in a locus-specific manner. In a
subsequent study by Cortellino et al., it was also shown using
Thymine DNA Glykosylase (TDG)-deficient mice that demethyla-
tion is an active process that requires TDG catalytic activity
immediately downstream of the deaminase-catalyzed conver-
sion of 5mC into thymine and/or 5hmC into 5hmU (Cortellino
et al., 2011). Coimmunoprecipitation experiments also revealed
that AID and TDG directly interact in a ternary complex with
growth arrest and DNA damage-inducible protein 45-a
(Gadd45a). Gadd45a is a genome stability protein known to
initiate demethylation in mammalian cells (Barreto et al., 2007;
Schmitz et al., 2009), Xenopus (Barreto et al., 2007), and zebra-
fish embryos via an AID/APOBEC-mediated deamination reac-
tion followed by removal of the mismatched thymine by the
zebrafish thymine glycosylase MBD4a (Rai et al., 2008).
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Figure 2. A Dual Role for TET1 in Transcriptional Regulation
(A) Schematic of TET1 binding profile in the genome of mouse ESCs. TET1
is most highly enriched at the transcriptional start site (TSS) of genes with
high-CpG-containing promoters (HCPs) compared with those with interme-
diate- and low-CpG-containing promoters (ICPs and LCPs, respectively).
(B) TET1 directly binds to the corepressors Sin3a and HDACs. TET1 target
genes cobound by polycomb repressor complex (PRC) proteins and Sin3a
are repressed and display bivalent H3K4me3 and H3K27me3 marks. (C)
TET1-only target genes are actively transcribed and enriched for H3K4me3
and H3K36me3.
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may also trigger DNA demethylation by BER independently of
deamination. Recently it has been shown that mouse ESCs,
iPSCs, and other organs contain low but detectable levels of
5caC in their genome (He et al., 2011; Ito et al., 2011). Using
an in vitro assay, He et al. identified glycosylase activity in mouse
ESC nuclear extracts specific only for 5caC-containing, and not
5hmC-containing, DNA substrates. Depletion of TDG in mouse
ESCs or iPSCs caused significant 5caC accumulation (He
et al., 2011), providing further evidence that TDG may act both
on 5hmU and 5caC, downstream of TET activity, to initiate
BER in vivo. These combined studies suggest that the role of
the TET proteins may be to prevent hypermethylation and
promote demethylation by a sequential process involving AID/
APOBEC-mediated deamination of 5mC to 5mU (Guo et al.,
2011; Cortellino et al., 2011) or further oxidation of 5hmC to
5caC followed by BER (Ito et al., 2011; He et al., 2011). Loss
of either AID or TDG alone, however, is not sufficient to
completely block DNA demethylation. Therefore, other DNA
repair pathways or unknown DNA demethylation mechanismsmay also contribute to the regulation of DNA methylation
patterns during developmental reprogramming events and
differentiation.
Genome-Wide Mapping of 5hmC and TET1 Binding
in the Mammalian Genome
Based on the findings that 5hmC is enriched in mouse ESCs
(Tahiliani et al., 2009) and neuronal cells (Kriaucionis and Heintz,
2009), several groups have employed 5hmC-specific immuno-
precipitation techniques to map its genomic distribution in
mouse ESCs (Ficz et al., 2011; Robertson et al., 2011; Williams
et al., 2011; Wu et al., 2011a; Xu et al., 2011b), human ESCs
(Stroud et al., 2011), and brain tissue (Jin et al., 2011; Song
et al., 2011).
5hmC in ESCs localizes mainly to transcriptional start sites
(TSSs) and within gene bodies, and in general is found more
highly enriched at gene exons as compared with introns (Ficz
et al., 2011; Williams et al., 2011; Wu et al., 2011a; Xu et al.,
2011b). This distribution is similar to that seen in mouse cere-
bellum (Song et al., 2011); however, in an adult human brain
study, there was greater enrichment for 5hmC in the promoter
region than in gene bodies (Jin et al., 2011), perhaps suggesting
differences in 5hmC distribution between species or during
maturation. The combined studies in ESCs for the most part
agree that 5hmC modifications are found predominantly local-
ized within gene bodies with intermediate-density CpG pro-
moters of both active and repressed genes.
TET1, unlike TET2 and TET3, possesses a CXXC zinc finger
DNA-binding motif and three candidate bipartite nuclear locali-
zation signals in its N terminal domain (Lorsbach et al., 2003).
Studies have shown that TET1 has a preference for binding
CpG-rich DNA (Xu et al., 2011b; Williams et al., 2011) and has
a high affinity for binding to nonmethylated CpG sequences,
which is similar to other CXXC-containing chromatin modifiers
such as DNMT and MLL (Zhang et al., 2010). It also significantly
binds to methylated CpG and 5hmC sequences (Xu et al.,
2011b), which would be consistent with its role in catalyzing
the conversion of 5mC to 5hmC (Zhang et al., 2010).
Given that TET1 is highly expressed in ESCs, and that loss of
TET1 expression causes a global decrease in 5hmC levels (Koh
et al., 2011), several groups also performed TET1 ChIP-seq anal-
ysis in parallel with genome-wide 5hmCmapping inmouse ESCs
that resulted in highly similar TET1 binding profiles (Figure 2A).
The consensus from studies thus far is that TET1 binds preferen-
tially at TSSs in promoters compared with gene bodies and does
so with an affinity that positively correlates with CpG density
(Williams et al., 2011; Wu et al., 2011b; Wu and Zhang, 2011;
Xu et al., 2011b). High-CpG-containing promoters (HCPs) are
bound most strongly by TET1 and display univalent H3K4me3
marks compared with intermediate-CpG-containing promoters
(ICPs), which are poorly bound by TET1 and display bivalent
H3K4me3 and H3K27me3, and very little TET1 binding is seen
at low-CpG-containing promoters (LCPs) that are univalent
H3K27me3. Interestingly, knockdown of TET1 causes an in-
crease in 5mC at TSS regions of its target genes and a partial
decrease in 5hmC at specific gene loci (Williams et al., 2011)
both at promoters and within gene bodies of TET1 target genes
(Wu et al., 2011a; Xu et al., 2011b). What remains unclear is how
loss of TET1 influences the 5hmC distribution of genes with ICPsCell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc. 195
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increasing toward the transcriptional termination site (TTS)
where there is negligible TET1 binding (Williams et al., 2011; Xu
et al., 2011b). It is interesting to speculate that lack of TET1
binding indirectly shifts the balance of 5hmC distribution from
the TSS toward the TTS, perhaps due to the activity of another
enzyme, such as TET2, which is also highly expressed in ESCs
but lacks the CXXC motif that would potentially target it to the
same CpG-rich regions in the promoters of genes recognized
by TET1.
Additional complexity is seen at the transcriptional level, with
TET1 playing a dual role in both activation and repression of its
target genes (Williams et al., 2011; Wu et al., 2011b; Xu et al.,
2011b) (Figures 2B and 2C). In all three studies, TET1 knockdown
causes more genes to become upregulated than downregulated
and TET1 binds directly to more of the upregulated genes. Inter-
estingly, two groups found extensive overlap between TET1 and
polycomb repressor complex (PRC) target genes, and despite
a requirement of TET1 for the transcriptional activity of PRC2
(Wu et al., 2011b), there was no direct interaction between these
proteins (Williams et al., 2011;Wu et al., 2011b). The corepressor
Sin3a was instead found to directly associate with TET1 and not
TET2 in a pull-down assay using HEK293 cells, and it showed
extensive overlap with TET1 in both binding profiles and target
genes (Williams et al., 2011). The direct association of Sin3a
and recruitment of PRC2 at the TSS of target genes bound by
TET1 may explain how TET1 plays a role as a transcriptional
repressor (Williams et al., 2011;Wu et al., 2011b). The perplexing
conclusion from these studies is that TET1 binding cannot
however be used to predict whether a gene will be activated or
repressed, and how activation could be mediated was not ad-
dressed. Subsequent studies will need to ascertain TET2 and
TET3 localization in the mammalian genome and to determine
if TET2 and TET3 can function as transcriptional repressors
in vitro, as has been shown for TET1.
Gene expression was also correlated to 5hmC mapping with
WT or TET1-deficient ESCs and associated histone modifica-
tions. In the study byWu et al., 5hmCwas preferentially enriched
at the TSS of lowly expressed genes that exhibit bivalent H3K4
and H3K27 trimethylation, consistent with TET1-repressed
PRC2 co-occupied target genes (Wu et al., 2011a, 2011b).
Instead, 5hmC is depleted at the TSS and enriched within gene
bodies peaking at the TTS in highly expressed genes that are
H3K4 and H3K36 trimethylated, consistent with TET1-mediated
gene activation (Wu et al., 2011a, 2011b).While TET1 is able bind
to genes that are expressed at either high or low levels (Wu et al.,
2011a; Xu et al., 2011b), Xu et al. identified two additional groups
of TET1-bound target genes that do not depend on TET1 for
transcriptional regulation: genes that are either silenced by
univalent H3K27me3 or highly expressed genes with abundant
H3K4me3 and H3K36me3 occupancy. That TET1 might influ-
ence chromatin accessibility independently of its effect on
gene transcription is exciting, but this requires further validation
using catalytically inactive, DNA-binding mutant or truncated
proteins and genetic approaches targeting TET proteins and
PRC complexes in tandem.
5hmC may play distinct roles in gene transcription in pluripo-
tent stem cells versus specialized cells such as neurons, partic-
ularly given that the correlation between gene expression and196 Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc.5hmC levels at promoters and gene bodies between ESCs (Wil-
liams et al., 2011; Xu et al., 2011b; Wu et al., 2011a) and mouse
cerebellum (Song et al., 2011) is different. Global 5hmC and
locus-specific 5hmC may be differentially regulated in different
cell types or at different stages of development, as is the case
during maturation in the brain (Song et al., 2011). From the
combined studies performed in ESCs it could be concluded
that TET1 and TET2, 5hmC, and its precursor 5mC are not
needed for ESC pluripotency, but are required for normal differ-
entiation during ESC lineage specification (Koh et al., 2011).
Further evidence for this proposal is provided by Dnmt TKO
ESCs, which lack both 5mC and 5hmC (Williams et al., 2011)
and are defective in differentiation (Jackson et al., 2004), yet
display only limited alteration in gene expression and can main-
tain self-renewal and an undifferentiated ESC state (Tsumura
et al., 2006). Lack of TET2 in hematopoietic cells may parallel
loss of TET1 in mouse ESCs and render myeloid progenitors
unable to achieve normal patterns of methylation that are asso-
ciated with differentiation but instead permit the stem cell self-
renewing state, a trait that may then contribute to leukemic
transformation in TET2-deficient mice (Moran-Crusio et al.,
2011; Quivoron et al., 2011; Li et al., 2011). Genome-wide
mapping of 5hmC in the hematopoietic system has not yet
been reported; however, it will be intriguing to see how this
epigenetic marker might change in distribution between HSC
and differentiated lineage-specific genomes. Given that all
three TET proteins exhibit differential expression in hematopoi-
etic cells (Lorsbach et al., 2003; Moran-Crusio et al., 2011;
Quivoron et al., 2011) it remains to be seen what the contribu-
tion of each TET will be in similar studies that employ ChIP-seq,
gene expression, and histone modification profiling in correla-
tion with 5hmC mapping.
Identification of TET2 Mutations in Myeloid
Malignancies
Initial reports of alterations involving the TET family of proteins
came in 2002 and 2003 when two groups identified TET1 as
a fusion partner of MLL in a small subset of patients with acute
myeloid leukemia associated with a t(10;11)(q22;q23) transloca-
tion (Lorsbach et al., 2003; Ono et al., 2002). Lorsbach, Downing,
and colleagues used homology searches to identify TET2 and
TET3 as members of the TET family, and demonstrated that all
three TET proteins were differentially expressed in different
tissue compartments with TET2 being most widely expressed,
including within the hematopoietic compartment (Lorsbach
et al., 2003). Notably, given that TET1 was fused to MLL in all
patients with the t(10;11)(q22;q23) translocation, functional
studies of TET1 or of the other TET proteins were not undertaken
at that time.
In 2009 two groups independently identified somatic alter-
ations in TET2 in patients with myeloproliferative neoplasms
(MPN) and myelodysplastic syndrome (MDS) (Delhommeau
et al., 2009; Langemeijer et al., 2009). Delhommeau and
colleagues investigated a subset of MPN patients with expan-
sion of the immature, CD34+ hematopoietic progenitor compart-
ment, and using comparative genomic hybridization and single
nucleotide polymorphism (SNP) arrays, they identified recurrent,
focal deletions and copy-neutral loss of heterozygosity (CN-
LOH) on chromosome 4q24. In one patient they mapped the
Figure 3. Schema of Somatic TET2 Mutations in Hematopoietic
Malignancies
Displayed are the known somatic missense, nonsense, and frameshift muta-
tions throughout the open reading frame of TET2 in myelodisplastic
syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myelomo-
nocytic leukemia (CMML), and acute myeloid leukemia (AML). In addition
mutations that were seen in more than one sample among studies are high-
lighted in yellow. Data are compiled from several studies (Abdel-Wahab et al.,
2009; Bejar et al., 2011; Delhommeau et al., 2009; Figueroa et al., 2010;
Jankowska et al., 2009; Koh et al., 2011).
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gene resequencing of TET2 and identified somatic mutations in
10%–20% of MPN and MDS patients. Langemeijer and
colleagues performed SNP array analysis of 102 patients with
MDS, and in five patients they identified focal deletions or CN-
LOH involving the region on chromosome 4q24, which includes
the TET2 locus. They then performed candidate gene se-
quencing and identified missense, nonsense, and frameshift
mutations in 26% of the patients in their MDS cohort. These
two landmark studies demonstrated that deletions, LOH, and
mutations are a frequent somatic event in MPN and MDS, and
the presence of nonsense/frameshift mutations and deletions
provides strong genetic evidence that TET2 mutations in
leukemia patients result in reduced/absent TET2 function.
Importantly, although these studies did not include extensive
functional analysis, Delhommeau and colleagues demonstrated
improved engraftment of TET2 mutant MPN cells in immunode-
ficient mice, consistent with enhanced stem cell function in vivo
(Delhommeau et al., 2009).
Clinical Spectrum of TET2Mutations in Hematopoietic
Malignancies
Subsequent to the discovery of TET2 mutations in MPN and
MDS patients, many studies have performed TET2 resequencing
in large cohorts of leukemia patients to delineate the frequency
of TET2 mutations in different malignancies (Figure 3), and to
investigate whether TET2mutations are associated with specific
clinical features or with poor outcome (Table 1). Many groups
have investigated TET2 mutations in MPN patients; the largest
studies suggest that TET2 mutations can be identified in 2%–
10% of polycythemia vera (PV) and essential thrombocytosis
(ET) patients, and in 10%–20% of patients with primary myelofi-
brosis (PMF) or post-PV/ET myelofibrosis (Abdel-Wahab et al.,
2009; Tefferi et al., 2009). Importantly, TET2 mutations are
observed at a higher frequency in MPN patients who transform
to acute myeloid leukemia (AML) patients, suggesting TET2
mutation is a common genetic event associated with leukemic
transformation (Abdel-Wahab et al., 2010). However, the prog-
nostic relevance of TET2 mutations in MPN has not been as-
sessed in sufficiently large cohorts to date. Similarly, many
groups have confirmed that TET2 mutations occur in 25%–
30% of MDS patients (Witkowski et al., 2009), and while smaller
studies suggested that TET2 mutations were associated with
adverse outcome in MDS, more recent investigation of a large
MDS cohort failed to demonstrate a relationship between TET2
mutations and poor prognosis (Bejar et al., 2011). TET2 muta-
tions also occur in almost 50% of patients diagnosed with
chronic myelomonocytic leukemia (CMML), an overlapping
malignancy with features of both MPN and MDS. Given the
CMML phenotype of TET2-deficient mice (Moran-Crusio et al.,
2011), it is notable that CMML is associated with the highest
frequency of TET2 mutations to date.
In addition, TET2 mutations are observed in a subset of
patients with AML. Initial studies identified TET2 mutations in
10% of AML patients, and found that TET2mutant AML patients
had poorer outcome compared with patients without TET2
mutations (Abdel-Wahab et al., 2009). Subsequent studies in
larger, homogenously treated cohorts of de novo AML patients
have confirmed that TET2 mutations occur in 7%–23% ofCell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc. 197
Table 1. Studies Evaluating the Potential Prognostic Significance of TET2 Mutations in Patients with Myeloid Malignancies
Disease Reference Patients Studied Prognostic Relevance
AML (Abdel-Wahab et al., 2009) 119 AML patients including de novo AML,
therapy-related AML, and AML with an
antecedent hematologic disorder
TET2 mutations were associated with
significantly worsened overall survival
AML (Nibourel et al., 2010) 111 patients with de novo AML TET2 mutations did not impact
overall survival
AML (Metzeler et al., 2011) 427 patients with normal karyotype AML TET2 mutations were associated with
a lower complete remission rate and shorter
disease-free and overall survival
Secondary AML (Kosmider et al., 2011) 247 patients with AML derived from
MDS or therapy-related AML
TET2 mutations did not influence complete
remission rates or overall survival
MDS (Kosmider et al., 2009a) 89 MDS patients and 7 with MDS
transformed to AML
TET2 mutations associated with
a significantly improved overall
and progression-free survival
MDS (Bejar et al., 2011) 439 de novo MDS patients TET2 mutations did not impact overall
survival or effect clinical characteristics
in an adverse way
MPN (Tefferi et al., 2009) 239 BCR-ABL-negative MPN patients TET2 mutations did not impact overall
survival or effect clinical characteristics
in an adverse way
CMML (Kosmider et al., 2009b) 88 patients with CMML TET2 mutations strongly associated with
monocytosis; in the overall cohort, TET2
mutations did impact survival, but TET2
imparted significantly worse overall survival
in patients with CMML I specifically
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mutations increases with increasing age (Figueroa et al., 2010;
Metzeler et al., 2011). Importantly, TET2 mutations were found
to be associated with adverse outcome in karyotypically normal
AML patients (Metzeler et al., 2011), suggesting that TET2muta-
tional status represents a novel biomarker that can be used to
improve risk stratification in AML and to select patients for
stem cell transplantation. By contrast, TET2 mutations occur
in a higher proportion of patients who transform from MPN
to AML, and studies of paired MPN and AML samples from
individual patients demonstrated that TET2 mutations are
commonly acquired in transformation to AML from a chronic
myeloid neoplasm (Abdel-Wahab et al., 2010), implicating
TET2 mutation as an important genetic event in conferring
self-renewal and acute leukemic transformation to chronic
myeloid malignancies.
Most recently, candidate gene resequencing of TET2 in hema-
tologic malignancies led to the identification of recurrent TET2
mutations in B and T cell lymphoid malignancies, including in
30% of patients with angioimmunoblastic T cell lymphoma
(Quivoron et al., 2011). In addition, they demonstrated that the
TET2 mutant clone could be identified in hematopoietic stem/
progenitor cells (HSPCs) from patients with T cell lymphoma,
suggesting that TET2 mutations are acquired in the stem cell
compartment in lymphoma patients without coexistent myeloid
disease. These data suggest that TET2 mutations are acquired
in HSPCs but that the disease phenotype associated with
TET2 mutation is dictated by the presence of known myeloid
(e.g. JAK2 or FLT3) or lymphoid disease alleles.198 Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc.Insights into Mechanisms of Transformation from
Investigation of Primary Patient Samples
As noted above, TET2mutant MPN samples exhibited improved
engraftment (Delhommeau et al., 2009), consistent with
improved stem-cell function of TET2 mutant HSPCs, which has
subsequently been confirmed in murine genetic studies (see
below). Importantly, two additional important insights have
emanated from studies of primary patient samples with TET2
mutations. Rao, Maciejewski, and colleagues assessed 5hmC
content in CMML patients with TET2 mutations and demon-
strated that TET2 mutant CMML is characterized by a marked
reduction in global levels of 5hmC (Ko et al., 2010); this has
subsequently been confirmed in MPN patients (Pronier et al.,
2011). In addition, they demonstrated that introduction of TET2
missense mutations seen in leukemia patients into the TET2
catalytic domain resulted in impaired hydroxymethylation. Taken
together, these data show that leukemia-associated TET2muta-
tions cause loss of function with respect to TET2-mediated
hydroxymethylation.
More recently, genetic studies in AML patients have provided
additional insight into the role of TET2 in leukemic transforma-
tion. Detailed genetic and methylation analysis of a large cohort
of AML patients led to the observation that TET2 mutant AML is
characterized by a hypermethylation phenotype (Figueroa et al.,
2010). This is consistent with the biochemical data establishing
5hmC as an intermediate to demethylated DNA, and suggests
that impaired hydroxymethylation leads to increased DNA
cytosine methylation in TET2 mutant AML patients. However,
in a separate study, TET2 loss of function was associated with
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Figure 4. Mutation of TET2 or IDH Proteins Is
Associated with Myeloid Malignancies and
Aberrant DNA Methylation
IDH proteins normally catalyze the conversion of NADP+
into NADPH and isocitrate into a-ketoglutarate (a-KG),
a substrate required for normal TET2 enzymatic activity.
Mutant IDH proteins cause loss of function of TET2 by
exhibiting neomorphic enzymatic activity that results in the
consumption of NADPH and production of the oncome-
tabolite 2-hydroxyglutarate (2-HG) instead of a-KG. IDH
mutations are mutually exclusive with TET2 mutations
found in patients that exhibit reduced hydroxylase activity,
due in part to mutations in the 2-OG and Fe(II)-dependant
dioxygenase domain that cause decreased 5hmC
production and aberrant DNA methylation patterns.
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Reviewhypomethylation rather than hypermethylation at differentially
methylated CpG sites (Ko et al., 2010). However, there are
important differences between these two studies; notably the
study by Figueora and colleagues focused on a large, homoge-
neous clinical trial cohort of patients with a single disease entity,
AML, and only included patient samples obtained at diagnosis
before patients received any treatment. By contrast, the work
by Koh and colleagues included a smaller, retrospective cohort
of heterogeneous primary samples from patients with CMML,
AML, MPN, MDS, and MPN/MDS overlap syndromes. As such
the discrepancies between these two studies likely reflect the
differences between the patient cohorts in these two studies,
and between the assays used to measure DNA methylation by
the two groups. Given that aberrant DNA methylation has been
shown to be an important pathogenetic mechanism in the
progression of MDS to AML (Jiang et al., 2009), it is likely that
the effects of TET2 mutations on cytosine methylation will differ
in different oncogenic contexts. Additional DNA methylation
profile studies are required that combine TET2mutational status,
5hmCmeasurements, and DNAmethylation analyses in patients
with MPN, MDS, and AML.
Recent mutational studies in AML have revealed that TET2
mutations are mutually exclusive with somatic mutations in the
isocitrate dehydrogenase genes IDH1 and IDH2 (Figueroa et al.,
2010). The IDH enzymes are NADP-dependent enzymes that
normally function as homodimers to catalyze the oxidative decar-
boxylation of isocitrate to a-KG with the concomitant production
ofNADPH (Figure4). Somaticmutations affecting residueR132of
IDH1 are found in over 70%of secondary glioblastomas (Parsons
et al., 2008; Yan et al., 2009); subsequent studies identified the
same recurrent somatic mutation in AML patients (Mardis et al.,
2009). Subsequent studies identified IDH2 mutations in glioma
and AML patients including mutations at codon R172 in glioma/
AML patients (Gross et al., 2010; Marcucci et al., 2010; Ward
et al., 2010; Yan et al., 2009) and at R140 in patients with AML;
notably, IDH2 R140 mutations are the most common IDH1/2
mutations seen in myeloid malignancies (Marcucci et al., 2010;
Ward et al., 2010). Mutation of IDH1 R132 and IDH2 R172 resi-
dues along with the novel AML mutation in IDH2, R140, are pre-Cell Stem Cdicted to interfere with the ability to bind the
b-carboxyl of isocitrate, and the initial studies
suggested that IDH1/2 mutations were purely
loss-of-function disease alleles (Yan et al.,
2009). However, subsequent studies demon-strated that the loss in the ability ofmutant IDHproteins to convert
isocitrate to a-KG is replaced by a neomorphic enzymatic func-
tion. Specifically, the mutant IDH proteins catalyze the NADPH-
dependent reduction of a-KG to 2-hydroxyglutarate (2-HG),
a rare metabolite present at very low levels in normal cells. IDH
mutant gliomasandAMLcells accumulate10- to 100-foldgreater
levels of 2-HG (Dang et al., 2009; Gross et al., 2010; Ward et al.,
2010), which can also be detected in elevated quantities in the
sera of IDH1/2mutant AML patients (Gross et al., 2010).
While these previous studies had shown that IDH mutations
were associated with aberrant production of 2-HG in AML and
glioblastoma multiforme patients (Dang et al., 2009; Gross
et al., 2010; Ward et al., 2010), the mechanism by which 2-HG
production contributed to oncogenic transformation had not
been elucidated. IDH1/2 mutant AML was also characterized
by increased cytosine methylation, suggesting a convergent
mechanism of transformation by TET2 and IDH1/2 mutant
disease alleles in AML. Given that the TET family of proteins
require a-KG for their enzymatic functioning, Figueora and
colleagues then investigated whether IDH1/2 mutants could
inhibit TET2 enzymatic activity, and demonstrated that coex-
pression of IDH mutant alleles with WT TET2 led to impaired
DNA hydroxymethylation (Figueroa et al., 2010). Subsequent
enzymatic studies demonstrated that direct exposure to 2-HG
directly inhibits TET2 enzymatic function (Xu et al., 2011a). In
addition, in vitro studies showed that ectopic expression of
IDH mutant alleles or shRNA-mediated depletion of TET2 led
to similar effects on hematopoietic differentiation (Figueroa
et al., 2010). These data demonstrate that a hypermethylation
signature characterizes TET2 mutant and IDH mutant leukemia,
and that neomorphic IDH mutations and TET2 loss-of-function
mutations converge on a shared mechanism of hematopoietic
transformation characterized by impaired hydroxymethylation.
In Vitro and In Vivo Models of Tet2 Deficiency: Effects
of Tet2 Deletion on HSC Differentiation and Induction
of Leukemia
The identification of TET2 mutations in myeloid neoplasms sug-
gested that TET2 function could be both an oncogenic triggerell 9, September 2, 2011 ª2011 Elsevier Inc. 199
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previously, mutational analysis suggested that the majority of
these mutations severely affect enzymatic activity by either in-
hibiting gene expression or the function of essential catalytic
domains of the protein. These studies underlined the need for
models of Tet2 deficiency in the hematopoietic system, to
directly address the function of this gene in both physiological
differentiation and leukemic transformation.
Rao and colleagues initially used RNAi-mediated Tet2-
silencing to address such questions. They reported that Tet2
knockdown in early hematopoietic progenitors affects myelo-
poiesis as it promotes expansion of monocyte-macrophage
cells in the presence of G-CSF and GM-CSF, which promote
granulocyte and granulocyte/monocyte differentiation, respec-
tively. No such effects were noted in the presence of M-CSF, a
cytokine promoting the development of monocytic progenitors
(Ko et al., 2010). More recently similar knockdown studies
were performed using human progenitor cells (Pronier et al.,
2011). TET2 silencing led to skewed differentiation toward the
myelo-monocytic lineage, at the expense of lymphopoiesis
and erythropoiesis. Interestingly, monocytic cell differentiation
was specifically favored, providing a possible explanation for
the high frequency of TET2mutations in CMML, a disease asso-
ciated with the expansion of the monocytic compartment.
A different outcome was reported in another recent study in
which primary bone marrow cells were infected with viruses
expressing either Tet2 shRNAs or mutant IDH2 molecules (thus
affecting Tet2 enzymatic activity). After culturing the cells on
both methylcellulose and liquid cultures, a higher percentage
of more immature c-Kit+ cells were observed (Figueroa et al.,
2010). Higher c-Kit levels suggested that Tet2 silencing is able
to suppress stem/progenitor cell differentiation and retain the
cells in a more immature state. In agreement with these studies,
Moran-Crusio and colleagues have shown that Tet2 silencing by
shRNA and by genetic deletion not only increases the c-Kit+
fraction, but increases the replating ability of the cells in vitro,
suggesting direct effects on self-renewal (Moran-Crusio et al.,
2011).
Although these studies provided valuable information of the
role of Tet2, hematopoiesis and leukemogenesis are dynamic
processes that can be optimally studied in vivo. Three recent
studies have reported the generation and analysis of Tet2-defi-
cient animals (Li et al., 2011; Moran-Crusio et al., 2011; Quivoron
et al., 2011). Interestingly, four different Tet2/ models were
described: (1) a ‘‘gene-trapped’’ Tet2 allele targeting a lacZ/
GFP cassette at the transcriptional start of Tet2, (2) a gene-trap-
ped allele targeting a lacZ cassette at the intron between exons 9
and 10, (3) a conditional allele targeting the first (and larger)
coding exon (exon 3) of the gene, and (4) a conditional allele
targeting exon 11, which encodes for the catalytic domain of
the enzyme. Although one of the gene-trapped alleles resulted
in a hypomorphic allele, and different Cre recombinase-deleter
strains were used for the deletion of the gene, all four mice led
to highly similar phenotypes, underlining the reproducibility of
the findings and mimicking the diverse mutational targets found
in human disease.
Tet2 deletion led to the progressive enlargement of the stem/
progenitor compartment (LineageSca1+c-Kit+, or LSK cells);
however, no compartment (defined by SLAM marker staining)200 Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc.was specifically enlarged. Strikingly, these mice developed
significant extramedullary hematopoiesis, with the appearance
of both LSK and myelo-erythroid progenitors in peripheral
lymphoid organs. These include bona fide HSCs as shown by
transplantation assays. Moreover, in addition to their relative
enlargement in absolute numbers, Tet2/HSCs have increased
self-renewing abilities as proven by both in vitro replating assays
and in vivo competitive transplantation experiments. Indeed,
Tet2/ total bone marrow and purified LSK cells have the ability
to serially replate. These cells express high levels of c-Kit and
remain arrested at a common myeloid progenitor-like (CMP)
stage. Whole-transcriptome analysis has shown that the replat-
ing premyeloblasts have downregulated expression of several
genes characteristic of myeloid differentiation, and upregulated
expression of genes indicative of stem cell self-renewal (c-Kit,
Evi1, and Meis1). Interestingly, previous studies of DNA methyl-
ation in TET2WT and TET2MUT patient samples identified the Evi1
promoter as differentially methylated in these two cell types,
suggesting that Tet2-mediated differential methylation of
specific gene targets could lead to restrained stem cell self-
renewal in normal HSPCs. Future studies that will map whole-
genome Tet2, 5hmC, and 5mC enrichment in distinct gene loci
during HSC differentiation will identify which TET2-regulated
genes are in fact direct Tet2 targets. We should mention here
that in all three studies, Tet2 deletion led to the loss of 5hmC,
consistent with the suggested enzymatic activity of the protein.
One of the most intriguing findings was the progressive devel-
opment of myeloid disease in all the animal models, starting at
4–6 months after the deletion of the gene. Although there were
slight differences in the diseaseonset and the kinetics of progres-
sion, most likely due to different backgrounds and efficiency/
mode of gene deletion, Tet2-deficient mice developed myeloid
neoplasms and predominantly CMML-like disease in agreement
with the high prevalence of TET2 mutations in human CMML
(Abdel-Wahab et al., 2009). Indeed, Tet2/ mice developed
progressive leukocytosis, splenomegaly, neutrophilia, blood
monocytosis, and myeloid dysplasia. Although CMML-like
disease was the most predominant, other types of neoplasms,
including MDS with erythroid predominance and MPD-like
disease, were detected in a fraction of the animals (Li et al.,
2011). These studies demonstrated that Tet2 functions as a
bona fide tumor suppressor and its deletion is sufficient to initiate
myeloid transformation. However, the kinetics of disease induc-
tion suggests that additional genetic lesions can cooperate with
Tet2 loss to induce leukemia. Indeed, Tet2 mutations co-occur
with a wide range of genetic lesions in both myeloid leukemia
(Klinakis et al., 2011) and lymphocytic neoplasms (Quivoron
et al., 2011). It is intriguing to speculate that these additional
genetic lesions not only cooperate with Tet2 mutation but also
influence the generation of distinct types of blood neoplasms.
Further experiments are required to address these issues.
Finally, all three studies demonstrated that Tet2+/ mice also
develop similar types of disease, albeit with slower kinetics.
These findings suggest a haploinsufficient tumor suppressor
function for Tet2 and are clinically important because the
majority of patients carry heterozygous TET2 mutations or dele-
tions. However, Tet2+/ mice develop disease with longer
latency and milder phenotype, suggesting gene-dosage effects.
Interestingly, all three TET family proteins are expressed in
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the upregulation of the expression of Tet1 and Tet3. It is thus
startling that reduction of the dosage of one of the three genes
(Tet2) is sufficient to induce significant 5hmCchanges, a skewing
in hematopoietic differentiation and development of myeloid
neoplasms. Further studies should focus on the relative redun-
dancy between the three proteins and putative interactions
between them in developing hematopoietic progenitor cells.
TET Protein Function and Role in the Differentiation
of Other Stem Cell Types
Germline deletion of Tet2 leads exclusively to hematopoietic
defects, suggesting that Tet2 plays a specific role in HSC differ-
entiation. However, to fully understand the role of Tet2 in other
adult stem cell compartments, further studies are required,
targeting specific stem cell types such as neural stem cells,
considering that substantial amounts of 5hmC have been de-
tected in brain tissue (Guo et al., 2011; Kriaucionis and Heintz,
2009) where Tet2 is also expressed (Lorsbach et al., 2003).
Although the study of TET protein function is in its infancy,
there is a significant amount of evidence suggesting their impor-
tance during ESC differentiation. Tet1 (and Tet2) are both
expressed in ESCs, and silencing of Tet1 affects self-renewal
and maintenance (Ito et al., 2010). Ito and colleagues reported
that Tet1 silencing leads to methylation of the Nanog promoter,
resulting in loss of Nanog expression and concomitant effects
in ESC differentiation. In the same study, Tet1 was shown to
be expressed in preimplantation embryos and play an essential
role in the specification of the cells of the inner cell mass (ICM).
Amore recent study further supported the idea that Tet1 function
is associated with ESC pluripotency, and suggested that Tet1
and Tet2 transcription itself is regulated by the master regulator
of ESC self-renewal, Oct4, by directly binding to 50UTR regula-
tory regions (Koh et al., 2011). This same study demonstrated
an altered developmental potential of Tet1-depleted ESCs, as
their differentiation is skewed toward the trophectoderm fate,
which is accompanied by the increased expression of Cdx2,
Eomes, and Elf2, and decreased expression of the Nodal antag-
onists Lefty1 and Lefty2. These and other studies indicated that
5hmC exists at significant levels in self-renewing ESCs and its
levels decline during differentiation (Szwagierczak et al., 2010;
Tahiliani et al., 2009; Xu et al., 2011b). Tet1 appears to be an
important regulator of 5hmC availability because its depletion
leads to a significant reduction of global 5hmC levels in ESCs
(Ito et al., 2011; Koh et al., 2011; Xu et al., 2011b). Furthermore,
it was shown that Tet1 regulates CpG methylation at promoters
of specific genes that could be essential mediators of ESC differ-
entiation. Intriguingly, last month in Cell Stem Cell, Jaenisch and
colleagues report the conditional deletion of Tet1 in ESCs and
early embryogenesis, and question the validity of the previous
in vitro studies. As expected, Tet1/ ESCs have reduced levels
of global 5hmC. However, the cells do not lose pluripotency
upon Tet1 deletion; express near-physiological levels of Nanog,
Oct4, and Sox2; and are able to support organism development
(Dawlaty et al., 2011). Indeed, Tet1/ animals are born at normal
Mendelian ratios and are fertile. In vitro, Tet1/ ESCs display
a skewing toward trophectoderm, in agreement with Koh et al.;
however, this phenotype is not recapitulated in vivo during
embryogenesis. These important data, together with the gener-ation of Tet2/ germline knockouts (Li et al., 2011; Moran-Cru-
sio et al., 2011; Quivoron et al., 2011), seriously question in vitro
findings suggesting that the ‘‘safest’’ way to study effects on
ESC pluripotency is to actually target the gene using homolo-
gous-recombination-based approaches. Further studies, in-
cluding generation of combined Tet gene knockouts, are
required to assess their role on DNA methylation and early
embryogenesis.
Conclusions
How both ESCs and HSCs utilize TET proteins and 5hmC modi-
fications as they differentiate from pluripotent stem cells into
adult cells is of great interest and under intense study. One of
the key upcoming challenges will be the detailed understanding
of TET family function in hematopoietic stem and progenitor cells
and the continued identification of TET binding partners and
target genes responsible for the establishment of leukemia.
Blood malignancies have been at the forefront of our under-
standing of the epigenetic regulation of cell transformation,
and targeting aberrant DNA methylation using hypomethylating
agents as an alternative to conventional chemotherapy is already
underway.
ACKNOWLEDGMENTS
We would like to thank the members of the Aifantis and Levine labs for critical
reading of the manuscript. I.A. is supported by the National Institutes of
Health (RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655, and
RO1GM088847), the Leukemia & Lymphoma Society (TRP grant), the Amer-
ican Cancer Society (RSG0806801), the V Foundation for Cancer Research,
the Irma T. Hirschl Trust, the Chemotherapy Foundation, the Dana Foundation,
and the Alex’s Lemonade Stand Foundation. L.C. is supported by a NHMRC
biomedical research fellowship. O.A.W. is a Basic Research Fellow of the
American Society of Hematology. This work was supported in part by grants
from the National Institutes of Health (U54CA143798-01, Physical Sciences
Oncology Center) and 1R01CA138234-01 to R.L.L., and by grants from
the Starr Cancer Consortium and Howard Hughes Medical Institute to R.L.L.
R.L.L. is a Geoffrey Beene Junior Faculty Chair at Memorial Sloan Kettering
Cancer Center. I.A. is a Howard Hughes Medical Institute Early Career
Scientist.
REFERENCES
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wa-
dleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009). Genetic
characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood 114, 144–147.
Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J., Hedvat, C.,
Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R.L., and Verstovsek,
S. (2010). Genetic analysis of transforming events that convert chronic myelo-
proliferative neoplasms to leukemias. Cancer Res. 70, 447–452.
Barreto, G., Scha¨fer, A., Marhold, J., Stach, D., Swaminathan, S.K., Handa, V.,
Do¨derlein, G., Maltry, N., Wu, W., Lyko, F., and Niehrs, C. (2007). Gadd45a
promotes epigenetic gene activation by repair-mediated DNA demethylation.
Nature 445, 671–675.
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-
Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D., and Ebert,
B.L. (2011). Clinical effect of point mutations in myelodysplastic syndromes.
N. Engl. J. Med. 364, 2496–2506.
Bhattacharya, S.K., Ramchandani, S., Cervoni, N., and Szyf, M. (1999).
A mammalian protein with specific demethylase activity for mCpG DNA.
Nature 397, 579–583.
Bhutani, N., Brady, J.J., Damian, M., Sacco, A., Corbel, S.Y., and Blau, H.M.
(2010). Reprogramming towards pluripotency requires AID-dependent DNA
demethylation. Nature 463, 1042–1047.Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc. 201
Cell Stem Cell
ReviewCortellino, S., Xu, J., Sannai, M., Moore, R., Caretti, E., Cigliano, A., Le Coz, M.,
Devarajan, K., Wessels, A., Soprano, D., et al. (2011). Thymine DNA glycosy-
lase is essential for active DNA demethylation by linked deamination-base
excision repair. Cell 146, 67–79.
Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M.,
Fantin, V.R., Jang, H.G., Jin, S., Keenan,M.C., et al. (2009). Cancer-associated
IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744.
Dawlaty, M.M., Ganz, K., Powell, B.E., Hu, Y.C., Markoulaki, S., Cheng, A.W.,
Gao, Q., Kim, J., Choi, S.W., Page, D.C., and Jaenisch, R. (2011). Tet1 is
dispensable for maintaining pluripotency and its loss is compatible with
embryonic and postnatal development. Cell Stem Cell 9, 166–175.
Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse´, A.,
Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., et al. (2009). Mutation
in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301.
Esteller, M. (2008). Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159.
Ficz, G., Branco, M.R., Seisenberger, S., Santos, F., Krueger, F., Hore, T.A.,
Marques, C.J., Andrews, S., and Reik, W. (2011). Dynamic regulation of
5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature
473, 398–402.
Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y.,
Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., et al. (2010). Leukemic
IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt
TET2 function, and impair hematopoietic differentiation. Cancer Cell 18,
553–567.
Gehring, M., Reik, W., and Henikoff, S. (2009). DNA demethylation by DNA
repair. Trends Genet. 25, 82–90.
Globisch, D., Mu¨nzel, M., Mu¨ller, M., Michalakis, S., Wagner, M., Koch, S.,
Bru¨ckl, T., Biel, M., and Carell, T. (2010). Tissue distribution of 5-hydroxyme-
thylcytosine and search for active demethylation intermediates. PLoS ONE
5, e15367.
Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang,
H.G., Sasaki, M., Jin, S., Schenkein, D.P., Su, S.M., et al. (2010). Cancer-asso-
ciated metabolite 2-hydroxyglutarate accumulates in acute myelogenous
leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med.
207, 339–344.
Guo, J.U., Su, Y., Zhong, C., Ming, G.L., and Song, H. (2011). Hydroxylation of
5-methylcytosine by TET1 promotes active DNA demethylation in the adult
brain. Cell 145, 423–434.
Hajkova, P., Erhardt, S., Lane, N., Haaf, T., El-Maarri, O., Reik, W., Walter, J.,
and Surani, M.A. (2002). Epigenetic reprogramming in mouse primordial germ
cells. Mech. Dev. 117, 15–23.
Hajkova, P., Ancelin, K., Waldmann, T., Lacoste, N., Lange, U.C., Cesari, F.,
Lee, C., Almouzni, G., Schneider, R., and Surani, M.A. (2008). Chromatin
dynamics during epigenetic reprogramming in the mouse germ line. Nature
452, 877–881.
Hajkova, P., Jeffries, S.J., Lee, C., Miller, N., Jackson, S.P., and Surani, M.A.
(2010). Genome-wide reprogramming in the mouse germ line entails the
base excision repair pathway. Science 329, 78–82.
He, Y.F., Li, B.Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li,
L., et al. (2011). Tet-Mediated Formation of 5-Carboxylcytosine and Its
Excision by TDG in Mammalian DNA. Science, in press. Published online
August 4, 2011. 10.1126/science.1210944.
Ito, S., D’Alessio, A.C., Taranova, O.V., Hong, K., Sowers, L.C., and Zhang, Y.
(2010). Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal
and inner cell mass specification. Nature 466, 1129–1133.
Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., He, C., and
Zhang, Y. (2011). Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcyto-
sine and 5-Carboxylcytosine. Science, in press. Published online July 21,
2011. 10.1126/science.1210597.
Jackson, M., Krassowska, A., Gilbert, N., Chevassut, T., Forrester, L., Ansell,
J., and Ramsahoye, B. (2004). Severe global DNA hypomethylation blocks
differentiation and induces histone hyperacetylation in embryonic stem cells.
Mol. Cell. Biol. 24, 8862–8871.
Jankowska, A.M., Szpurka, H., Tiu, R.V., Makishima, H., Afable, M., Huh, J.,
O’Keefe, C.L., Ganetzky, R., McDevitt, M.A., and Maciejewski, J.P. (2009).202 Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc.Loss of heterozygosity 4q24 and TET2 mutations associated with myelodys-
plastic/myeloproliferative neoplasms. Blood 113, 6403–6410.
Jiang, Y., Dunbar, A., Gondek, L.P., Mohan, S., Rataul, M., O’Keefe, C.,
Sekeres, M., Saunthararajah, Y., and Maciejewski, J.P. (2009). Aberrant DNA
methylation is a dominant mechanism in MDS progression to AML. Blood
113, 1315–1325.
Jin, S.G., Wu, X., Li, A.X., and Pfeifer, G.P. (2011). Genomic mapping of
5-hydroxymethylcytosine in the human brain. Nucleic Acids Res. 39, 5015–
5024.
Khachatryan, V., Sirunyan, A.M., Tumasyan, A., Adam, W., Bergauer, T.,
Dragicevic, M., Ero¨, J., Fabjan, C., Friedl, M., Fru¨hwirth, R., et al; CMS
Collaboration. (2011). Search for stopped Gluinos in pp collisions at square
root s=7 TeV. Phys. Rev. Lett. 106, 011801.
Klinakis, A., Lobry, C., Abdel-Wahab, O., Oh, P., Haeno, H., Buonamici, S., van
De Walle, I., Cathelin, S., Trimarchi, T., Araldi, E., et al. (2011). A novel tumour-
suppressor function for the Notch pathway in myeloid leukaemia. Nature 473,
230–233.
Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala,
H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., et al. (2010). Impaired
hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Nature 468, 839–843.
Koh, K.P., Yabuuchi, A., Rao, S., Huang, Y., Cunniff, K., Nardone, J., Laiho, A.,
Tahiliani, M., Sommer, C.A., Mostoslavsky, G., et al. (2011). Tet1 and Tet2
regulate 5-hydroxymethylcytosine production and cell lineage specification
in mouse embryonic stem cells. Cell Stem Cell 8, 200–213.
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard,
F., Viguie´, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., et al; Groupe Franco-
phone des Mye´lodysplasies. (2009a). TET2 mutation is an independent
favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood
114, 3285–3291.
Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N.,
Quesnel, B., Fenaux, P., Bastie, J.N., Beyne-Rauzy, O., et al; Groupe Franco-
phone des Mye´lodysplasies. (2009b). TET2 gene mutation is a frequent and
adverse event in chronic myelomonocytic leukemia. Haematologica 94,
1676–1681.
Kosmider, O., Delabesse, E., de Mas, V.M., Cornillet-Lefebvre, P., Blanchet,
O., Delmer, A., Recher, C., Raynaud, S., Bouscary, D., Viguie´, F., et al;
GOELAMS Investigators. (2011). TET2 mutations in secondary acute myeloid
leukemias: a French retrospective study. Haematologica 96, 1059–1063.
Kriaucionis, S., and Heintz, N. (2009). The nuclear DNA base 5-hydroxyme-
thylcytosine is present in Purkinje neurons and the brain. Science 324,
929–930.
Langemeijer, S.M., Kuiper, R.P., Berends, M., Knops, R., Aslanyan, M.G.,
Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A.G.,
Raymakers, R.A., et al. (2009). Acquired mutations in TET2 are common in
myelodysplastic syndromes. Nat. Genet. 41, 838–842.
Lee, J., Inoue, K., Ono, R., Ogonuki, N., Kohda, T., Kaneko-Ishino, T., Ogura,
A., and Ishino, F. (2002). Erasing genomic imprinting memory in mouse clone
embryos produced from day 11.5 primordial germ cells. Development 129,
1807–1817.
Li, E., Bestor, T.H., and Jaenisch, R. (1992). Targeted mutation of the DNA
methyltransferase gene results in embryonic lethality. Cell 69, 915–926.
Li, Z., Cai, X., Cai, C., Wang, J., Zhang, W., Petersen, B.E., Yang, F.C., and Xu,
M. (2011). Deletion of Tet2 in mice leads to dysregulated hematopoietic stem
cells and subsequent development of myeloid malignancies. Blood, in press.
Published online July 29, 2011. 10.1182/blood-2010-12-325241.
Lorsbach, R.B., Moore, J., Mathew, S., Raimondi, S.C., Mukatira, S.T., and
Downing, J.R. (2003). TET1, a member of a novel protein family, is fused to
MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia
17, 637–641.
Ma, D.K., Jang, M.-H., Guo, J.U., Kitabatake, Y., Chang, M.-l., Pow-anpong-
kul, N., Flavell, R.A., Lu, B., Ming, G.-I, and Song, H. (2009). Neuronal
Activity–Induced Gadd45b Promotes Epigenetic DNA Demethylation and
Adult Neurogenesis. Science 323, 1074–1077.
Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mro´zek, K., Margeson,
D., Holland, K.B., Whitman, S.P., Becker, H., Schwind, S., et al. (2010). IDH1
Cell Stem Cell
Reviewand IDH2 gene mutations identify novel molecular subsets within de novo
cytogenetically normal acutemyeloid leukemia: a Cancer and Leukemia Group
B study. J. Clin. Oncol. 28, 2348–2355.
Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K.,
Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., et al. (2009).
Recurringmutations found by sequencing an acutemyeloid leukemia genome.
N. Engl. J. Med. 361, 1058–1066.
Mayer, W., Niveleau, A., Walter, J., Fundele, R., and Haaf, T. (2000). Demethy-
lation of the zygotic paternal genome. Nature 403, 501–502.
Metzeler, K.H., Maharry, K., Radmacher, M.D., Mro´zek, K., Margeson, D.,
Becker, H., Curfman, J., Holland, K.B., Schwind, S., Whitman, S.P., et al.
(2011). TET2 mutations improve the new European LeukemiaNet risk classifi-
cation of acute myeloid leukemia: a Cancer and Leukemia Group B study.
J. Clin. Oncol. 29, 1373–1381.
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D.,
Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., et al.
(2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal
and myeloid transformation. Cancer Cell 20, 11–24.
Mu¨nzel, M., Globisch, D., Bru¨ckl, T., Wagner, M., Welzmiller, V., Michalakis, S.,
Mu¨ller, M., Biel, M., and Carell, T. (2010). Quantification of the sixth DNA base
hydroxymethylcytosine in the brain. Angew. Chem. Int. Ed. Engl. 49, 5375–
5377.
Muramatsu, M., Sankaranand, V.S., Anant, S., Sugai, M., Kinoshita, K.,
Davidson, N.O., and Honjo, T. (1999). Specific expression of activation-
induced cytidine deaminase (AID), a novel member of the RNA-editing
deaminase family in germinal center B cells. J. Biol. Chem. 274, 18470–
18476.
Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., and
Honjo, T. (2000). Class switch recombination and hypermutation require
activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.
Cell 102, 553–563.
Nibourel, O., Kosmider, O., Cheok, M., Boissel, N., Renneville, A., Philippe, N.,
Dombret, H., Dreyfus, F., Quesnel, B., Geffroy, S., et al. (2010). Incidence and
prognostic value of TET2 alterations in de novo acute myeloid leukemia
achieving complete remission. Blood 116, 1132–1135.
Okano, M., Bell, D.W., Haber, D.A., and Li, E. (1999). DNA methyltransferases
Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian
development. Cell 99, 247–257.
Ono, R., Taki, T., Taketani, T., Taniwaki, M., Kobayashi, H., and Hayashi, Y.
(2002). LCX, leukemia-associated protein with a CXXC domain, is fused to
MLL in acute myeloid leukemia with trilineage dysplasia having
t(10;11)(q22;q23). Cancer Res. 62, 4075–4080.
Oswald, J., Engemann, S., Lane, N., Mayer, W., Olek, A., Fundele, R., Dean,
W., Reik, W., and Walter, J. (2000). Active demethylation of the paternal
genome in the mouse zygote. Curr. Biol. 10, 475–478.
Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., Man-
koo, P., Carter, H., Siu, I.M., Gallia, G.L., et al. (2008). An integrated genomic
analysis of human glioblastoma multiforme. Science 321, 1807–1812.
Penn, N.W., Suwalski, R., O’Riley, C., Bojanowski, K., and Yura, R. (1972).
The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid.
Biochem. J. 126, 781–790.
Popp, C., Dean, W., Feng, S., Cokus, S.J., Andrews, S., Pellegrini, M., Jacob-
sen, S.E., and Reik, W. (2010). Genome-wide erasure of DNA methylation
in mouse primordial germ cells is affected by AID deficiency. Nature 463,
1101–1105.
Pronier, E., Almire, C., Mokrani, H., Vasanthakumar, A., Simon, A., da Costa
Reis Monte Mor, B., Masse´, A., Le Coue´dic, J.P., Pendino, F., Carbonne, B.,
et al. (2011). Inhibition of TET2-mediated conversion of 5-methylcytosine
to 5-hydroxymethylcytosine disturbs erythroid and granulo-monocytic differ-
entiation of human hematopoietic progenitors. Blood, in press. Published on-
line July 6, 2011. 10.1182/blood-2010-12-324707.
Quivoron, C., Couronne´, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon,
O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.H., et al. (2011).
TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities inMouse
and Is a Recurrent Event during Human Lymphomagenesis. Cancer Cell 20,
25–38.Rai, K., Huggins, I.J., James, S.R., Karpf, A.R., Jones, D.A., and Cairns, B.R.
(2008). DNA demethylation in zebrafish involves the coupling of a deaminase,
a glycosylase, and gadd45. Cell 135, 1201–1212.
Robertson, J., Robertson, A.B., andKlungland,A. (2011). Thepresenceof 5-hy-
droxymethylcytosine at the gene promoter and not in the gene body negatively
regulates gene expression. Biochem. Biophys. Res. Commun. 411, 40–43.
Schmitz, K.M., Schmitt, N., Hoffmann-Rohrer, U., Scha¨fer, A., Grummt, I., and
Mayer, C. (2009). TAF12 recruits Gadd45a and the nucleotide excision repair
complex to the promoter of rRNA genes leading to active DNA demethylation.
Mol. Cell 33, 344–353.
Song,C.X., Szulwach,K.E., Fu,Y.,Dai,Q.,Yi,C., Li,X., Li,Y.,Chen,C.H.,Zhang,
W., Jian, X., et al. (2011). Selective chemical labeling reveals the genome-
wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 29, 68–72.
Stroud, H., Feng, S., Morey Kinney, S., Pradhan, S., and Jacobsen, S.E. (2011).
5-Hydroxymethylcytosine is associated with enhancers and gene bodies in
human embryonic stem cells. Genome Biol. 12, R54.
Surani, M.A., Hayashi, K., and Hajkova, P. (2007). Genetic and epigenetic
regulators of pluripotency. Cell 128, 747–762.
Szwagierczak, A., Bultmann, S., Schmidt, C.S., Spada, F., and Leonhardt, H.
(2010). Sensitive enzymatic quantification of 5-hydroxymethylcytosine in
genomic DNA. Nucleic Acids Res. 38, e181.
Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y.,
Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., and Rao, A. (2009). Conversion
of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL
partner TET1. Science 324, 930–935.
Tefferi, A., Pardanani, A., Lim, K.H., Abdel-Wahab, O., Lasho, T.L., Patel, J.,
Gangat, N., Finke, C.M., Schwager, S., Mullally, A., et al. (2009). TET2
mutations and their clinical correlates in polycythemia vera, essential thrombo-
cythemia and myelofibrosis. Leukemia 23, 905–911.
Teng, B., Burant, C.F., and Davidson, N.O. (1993). Molecular cloning of
an apolipoprotein Bmessenger RNA editing protein. Science 260, 1816–1819.
Tsumura, A., Hayakawa, T., Kumaki, Y., Takebayashi, S., Sakaue, M.,
Matsuoka, C., Shimotohno, K., Ishikawa, F., Li, E., Ueda, H.R., et al. (2006).
Maintenance of self-renewal ability of mouse embryonic stem cells in the
absence of DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b. Genes
Cells 11, 805–814.
Valinluck, V., and Sowers, L.C. (2007). Endogenous cytosine damage products
alter the site selectivity of human DNA maintenance methyltransferase
DNMT1. Cancer Res. 67, 946–950.
Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A.,
Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., et al. (2010). The common
feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic
enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer
Cell 17, 225–234.
Williams, K., Christensen, J., Pedersen, M.T., Johansen, J.V., Cloos, P.A.,
Rappsilber, J., and Helin, K. (2011). TET1 and hydroxymethylcytosine in tran-
scription and DNA methylation fidelity. Nature 473, 343–348.
Witkowski, A., Maciejewski, P., Wasek, W., Malek, L.A., Niewada, M., Kamin-
ski, B., Drzewiecki, J., Kosmider, M., Kubica, J., Ruzyllo, W., et al; STEMI 2003
Registry Collaborators. (2009). Influence of different antiplatelet treatment
regimens for primary percutaneous coronary intervention on all-cause
mortality. Eur. Heart J. 30, 1736–1743.
Wu, H., and Zhang, Y. (2011). Tet1 and 5-hydroxymethylation: A genome-wide
view in mouse embryonic stem cells. Cell Cycle 10, 2428–2436.
Wu, H., D’Alessio, A.C., Ito, S., Wang, Z., Cui, K., Zhao, K., Sun, Y.E., and
Zhang, Y. (2011a). Genome-wide analysis of 5-hydroxymethylcytosine
distribution reveals its dual function in transcriptional regulation in mouse
embryonic stem cells. Genes Dev. 25, 679–684.
Wu, H., D’Alessio, A.C., Ito, S., Xia, K., Wang, Z., Cui, K., Zhao, K., Sun, Y.E.,
and Zhang, Y. (2011b). Dual functions of Tet1 in transcriptional regulation in
mouse embryonic stem cells. Nature 473, 389–393.
Xu,W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C.,Wang,
P., Xiao, M.T., et al. (2011a). Oncometabolite 2-hydroxyglutarate is a
competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer
Cell 19, 17–30.Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc. 203
Cell Stem Cell
ReviewXu, Y., Wu, F., Tan, L., Kong, L., Xiong, L., Deng, J., Barbera, A.J., Zheng, L.,
Zhang, H., Huang, S., et al. (2011b). Genome-wide regulation of 5hmC, 5mC,
and gene expression by Tet1 hydroxylase inmouse embryonic stem cells. Mol.
Cell 42, 451–464.
Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos,
I., Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. (2009). IDH1 and IDH2
mutations in gliomas. N. Engl. J. Med. 360, 765–773.204 Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc.Zhang, H., Zhang, X., Clark, E., Mulcahey, M., Huang, S., and Shi, Y.G. (2010).
TET1 is a DNA-binding protein that modulates DNA methylation and
gene transcription via hydroxylation of 5-methylcytosine. Cell Res. 20, 1390–
1393.Zhu, J.K. (2009). Active DNA demethylation mediated by DNA glycosylases.
Annu. Rev. Genet. 43, 143–166.
